Introduction: Comorbid substance abuse is known to blunt response to treatment for underlying psychiatric disorders, but it has not been investigated in schizophrenia when comparing the effects of long-acting injectable antipsychotics with those of oral antipsychotics. Methods: This exploratory analysis compared once-monthly paliperidone palmitate (PP1M) with daily oral antipsychotics on time to treatment failure in patients with schizophrenia and a history of incarceration. Subjects were stratified into substance abuse (reported substance or alcohol misuse in the past 30 days on the baseline Addiction Severity Index-Lite Version and/or met criteria for a current MINI diagnosis of a substance abuse disorder) and nonabuse cohorts. Results: In the substance abuse cohort, treatment failure was observed in 56.2% (73/130) and 64.2% (86/134) of subjects in the PP1M and oral antipsychotic groups, respectively. For the nonabuse cohort, treatment failure was observed in 36.5% (35/96) and 53.6% (45/84) of subjects in the PP1M and oral antipsychotic groups, respectively. Median (95% confidence interval [CI]) time to first treatment failure was 291 (179-428) days and 186 (94-296) days in the PP1M and oral antipsychotic groups, respectively. Median (95% CI) time to first treatment failure was 284 (147 to N 450) and N450 days in the respective treatment groups. Conclusion: Greater treatment effects were evident with PP1M compared with oral antipsychotics in both cohorts. The observed beneficial effect of PP1M was attenuated in the substance-abuse cohort, further reinforcing both the need for and value of continued research to optimize patient care in these complex patient populations.
Introduction
Schizophrenia is a chronic, serious mental illness affecting approximately 1.1% of US adults annually, whose disease course is frequently complicated by cognitive dysfunction, comorbid substance abuse, poor and unstable living conditions, multiple hospitalizations, and arrests/incarcerations (Regier et al., 1993; National Institute of Mental Health, 2016; Hoge, 2007; Folsom and Jeste, 2002; Ascher-Svanum et al., 2010) . As a consequence of these comorbidities and resulting psychosocial instabilities, many patients exhibit nonadherence to essential antipsychotic medications, thus increasing their risk for relapses and hospitalizations (Lang et al., 2010; Novick et al., 2010; Higashi et al., 2013) . Long-acting injectable (LAI) antipsychotic medications provide therapeutic plasma concentrations that are sustained over several weeks and with some, such as once-monthly paliperidone palmitate (PP1M), achieved within days of administration, thereby eliminating the need for adherence to daily oral antipsychotics (Pandina et al., 2010; Pandina et al., 2011) . LAIs can also improve the consistency of antipsychotic medication delivery over a period of weeks to months, increasing the duration of effective symptom control and reducing the risk of relapse (Berwaerts et al., 2015) .
Substance abuse is a common comorbidity in individuals with schizophrenia. It contributes to suboptimal adherence to treatment, poor symptom control, loss of function, increased suicidality, hospitalization, and a disproportionate increase in contact with the criminal justice system (CJS) (Gut-Fayand et al., 2001; Greenberg et al., 2011; Picci et al., 2013; Dumais et al., 2011; Lang et al., 2010; Novick et al., 2010; Higashi et al., 2013) . As such, this subpopulation is difficult to treat and represents an important public health problem (Ascher-Svanum et al., 2010; Greenberg et al., 2011; National GAINS Center, 2001 ).
Numerous prior studies document lower adherence to treatment plans and poorer treatment responses among substance-abusing patients (Picci et al., 2013; Lang et al., 2010; Ascher-Svanum et al., 2006; Greenberg et al., 2011; Novick et al., 2010; Hoge, 2007) . Substance abuse, and consequent nonadherence to treatment, has been linked to an increased risk of psychosis and symptom exacerbation (Fenton et al., 1997; Lacro et al., 2002; Ascher-Svanum et al., 2010; Olivares et al., 2013; San et al., 2013) as well as increased CJS contact, incarceration, and risk of hospitalization (Olivares et al., 2013; San et al., 2013) . The present study explores the negative impact of substance abuse and whether it is completely mitigated in this population despite the assured adherence associated with injectable drugs.
PRIDE (Paliperidone Palmitate Research in Demonstrating Effectiveness) was a prospective, randomized study that compared the effects of PP1M with daily oral antipsychotics on time to treatment failure. PRIDE incorporated both explanatory (efficacy) and pragmatic (effectiveness) design elements to better reflect real-world schizophrenia patients, treatments, and outcomes (Alphs et al., 2014) . This was achieved by including subjects with a history of incarceration and comorbid substance abuse, allowing considerable flexibility in treatment and management decisions, and including a range of real-world outcomes as endpoints (i.e., arrest/incarceration, hospitalization, or treatment discontinuation for reasons of poor tolerability or inadequate efficacy) (Alphs et al., 2014) . The time to first treatment failure (the primary endpoint for the PRIDE study), was significantly delayed by PP1M compared with daily oral antipsychotics, with a difference in median time to treatment failure of 190 days that favored the PP1M arm (P = 0.011) (Alphs et al., 2015) . The time to first psychiatric hospitalization or arrest/incarceration was also significantly delayed by PP1M compared with daily oral antipsychotics (P = 0.019). Median time to first psychiatric arrest/incarceration was not reached with PP1M (N450 days) and was 274 days in the oral antipsychotic group (Alphs et al., 2015) . Given the unusual inclusion of patients who met criteria for comorbid substance abuse in a long-term prospective interventional study in schizophrenia, the objective of the current post hoc analysis is to explore whether the greater effect of PP1M on treatment response compared with daily oral antipsychotics persisted in a subpopulation of schizophrenia patients with comorbid substance abuse and a history of recent incarceration.
Materials and methods

Study design
PRIDE was a prospective, randomized, open-label, event-monitoring board-blinded, active-controlled, multicenter US study (NCT01157351) (Alphs et al., 2014; Alphs et al., 2015) . The study included a screening phase of up to 2 weeks, followed by a 15-month randomized treatment phase. All subjects were encouraged to continue in the study for the full 15-month study period, regardless of early discontinuation from randomized treatment or whether they experienced a primary study endpoint. The current exploratory post hoc analysis was based on the pragmatic intent-to-treat (pITT) analysis set. In contrast to an explanatory approach, which tends to limit evaluation of treatment response to the period when subjects receive their randomly assigned medication, this pragmatic approach examined treatment effects until the 15-month endpoint (or final recorded observation), regardless of whether subjects were maintained on their initial randomized treatment (Alphs et al., 2014) , and therefore more closely reflects real-world outcomes.
Study population
The PRIDE study population has been previously described (Alphs et al., 2014; Alphs et al., 2015) . In brief, the key inclusion criteria were adults aged 18 to 65 years with a current diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV], criteria) (American Psychiatric Association, 2000) as confirmed by the M.I.N.I. International Neuropsychiatric Interview (MINI), version 6.0 (Cacciola et al., 2007) ; contact with the CJS (i.e., taken into custody) with ≥ 1 instance of custody leading to incarceration in the previous 2 years; and release from most recent CJS custody within 90 days of screening. Subjects were excluded if they had been actively abusing intravenous drugs within the past 3 months or had an opiate dependence disorder. Otherwise, substance abuse was not an exclusionary factor.
In the current analysis, subjects were included in the substance abuse cohort if they reported substance or alcohol misuse in the past 30 days on the baseline Addiction Severity Index-Lite Version (ASILite) (Cacciola et al., 2007) and/or met the criteria for a current MINI diagnosis of a substance abuse disorder (Cacciola et al., 2007) . This definition was consistent with DSM-IV criteria, which was used at the time of study execution (Sheehan et al., 1998) . Nicotine was not included in the list of substances of abuse.
Treatments
Treatment details for subjects enrolled in the PRIDE study have been previously reported (Alphs et al., 2014; Alphs et al., 2015) . In brief, antipsychotic treatment for individual subjects was randomly assigned (1:1) to flexibly dosed PP1M (78-234 mg) or daily oral antipsychotic therapy using an equipoise-stratified randomization scheme. The equipoised stratum was defined by the set of suitable oral antipsychotic treatments selected by the principal investigator and patients prior to randomization.
Assessments
The primary endpoint was defined as the time from subject randomization to occurrence of their first treatment failure. A treatment failure included any of the following events: arrest or incarceration, psychiatric hospitalization, suicide, discontinuation of treatment due to inadequate efficacy, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of treatment due to safety or tolerability, or increase in psychiatric services to prevent imminent psychiatric hospitalization. Safety assessments included monitoring of treatment-emergent adverse events (TEAEs).
Statistical analysis
The primary objectives of this exploratory analysis were to determine if the treatment effect of PP1M differed from the treatment effect with oral antipsychotics in (1) the nonabuse cohort and (2) the substance abuse cohort. Exploratory analyses included data from all subjects who received at least one dose of their randomly assigned study drug during the entire 15-month follow-up period regardless of whether they were still taking their randomized study medication (pITT analysis set). Demographic, baseline clinical characteristics, and TEAEs were summarized using descriptive statistics. Time to first treatment failure was estimated using the Kaplan-Meier method. Hazard ratio and treatment differences were estimated using the Cox proportional hazards regression model with treatment group (PP1M vs oral antipsychotics) and covariates for multiple prior incarcerations (yes/no), and whether subjects were randomized to the same medications they were taking before study entry (yes/no). No adjustments were made for multiplicity.
Results
Subjects and disposition
A total of 450 subjects were randomized. Of these, 269 subjects (60% of total population) were included in the comorbid substance abuse cohort and 181 (40%) were included in the nonabuse cohort. The pITT analysis comprised 264 subjects in the substance abuse cohort and 180 subjects in the nonabuse cohort. Study discontinuation due to an adverse event occurred in a total of 1.9% subjects in the substance abuse cohort (PP1M: 2.3%; oral antipsychotics: 1.5%) and 2.2% of subjects in the nonabuse cohort (PP1M: 2.1%; oral antipsychotics: 2.4%). Most demographic and baseline clinical characteristics of subjects in the substance abuse and nonabuse cohorts were similar between the PP1M and oral antipsychotic treatment groups (Table 1) . Overall, the majority of subjects were male and black/African American. Mean (standard deviation [SD] ) ages in the overall substance abuse and nonabuse cohorts were 37.8 (10.2) and 38.7 (10.8) years, respectively. The highest monthly income in the prior 12 months was less than $750 in the majority of subjects, with similar proportions between the abuse and nonabuse cohorts. Homelessness since release from jail was more common in the substance abuse cohort (18.2%) than in the nonabuse cohort (8.7%). Unemployment since release from jail was less common in the substance abuse cohort (85.5%) compared to the nonabuse cohort (91.1%). Polysubstance use (where more than one substance was used per day) was highly prevalent among subjects in the substance abuse cohort (61.7%; n = 161/261) compared with the nonabuse cohort (45.6%; n = 68/149), who, despite their polysubstance use, did not meet the study criteria for substance abuse. According to the data reported in ASI-Lite, the most commonly used substances (in past 30 days or lifetime) in the substance abuse cohort (n = 261) were alcohol (any use), 95.0% (n = 248); cannabis, 85.4% (n = 223); cocaine, 62.5% (n = 163); and amphetamines, 29.5% (n = 77).
Treatment failure outcomes (pITT analysis set)
Overall, the main comparisons made within this study were between treatment groups (PP1M vs oral antipsychotics) in patients with and without comorbid substance abuse. An analysis of treatment outcome revealed an overall higher risk of treatment failure with oral antipsychotic therapy compared with PP1M in both cohorts (Fig. 1) . Within the substance abuse cohort, subjects receiving oral antipsychotics exhibited treatment failure in 64.2% (86/134) of cases versus 56.2% (73/130) of those receiving PP1M treatment. The median (95% CI) time to first treatment failure was measured at 186 (94-296) days in the oral antipsychotic treatment group and 291 (179-428) days in the PP1M treatment group (Table 2) . Within the nonabuse cohort, subjects receiving oral antipsychotics exhibited treatment failure in 53.6% Psychiatric hospitalizations in lifetime, n, mean (SD) n = 105 n = 110 n = 70 n = 61 8. 4 (20.5) 5.2 (5.0) 5.8 (6.2) 6.5 (6.5)
Psychiatric hospitalizations in the past 12 months, n, mean (SD) n = 105 n = 110 n = 70 n = 64 1.7 (9.7) 1.0 (1.6) 0.7 (1.0) 1.0 (1.3) PSP total score, mean (SD) n = 130 n = 132 n = 96 n = 83 54.9 (13.1) 55.1 (12.7) 54.6 (12.6) 54.8 (12.8)
CGI-S score, mean (SD) n = 130 n = 133 n = 96 n = 84 3.9 (0.7) 3.9 (0.7) 3.8 (0.9) 3.8 (0.8) BMI, body mass index; CGI-S, Clinical Global Impressions-Severity scale; PP1M, once-monthly paliperidone palmitate; PSP, Personal and Social Performance scale; SD, standard deviation. a Living in a house or apartment alone (with no professional mental health support) or with others (e.g., parents, sibling, spouse, friend, children). b Living on the streets or in an emergency shelter for the homeless. c Full-time, part-time, or intermittent employment. d Over the past 12 months. Fig. 1 . Kaplan-Meier estimate of time to first treatment failure for once-monthly paliperidone palmitate versus daily oral antipsychotics in schizophrenia patients in the (A) substance abuse cohort and (B) nonabuse cohort (pragmatic intent-to-treat analysis set). CI, confidence interval; HR, hazard ratio; PP1M, once-monthly paliperidone palmitate. (45/84) of cases versus 36.5% (35/96) of those receiving PP1M ( Table 2 ). The median (95% CI) time to first treatment failure was 284 (147 to N450) and N450 days in these respective treatment groups. Treatment failure details are provided in Fig. 2A Substance abuse was associated with a higher incidence of arrest/incarceration in both PP1M and oral antipsychotic treatment groups ( Fig. 2A  and 2B ).
Psychiatric hospitalization or arrest/incarceration (pITT analysis set)
In the substance abuse cohort, the median (95% CI) time to first psychiatric hospitalization or arrest/incarceration was 317 (194 to N 450) days and 371 (247 to N450) days, for oral antipsychotic and PP1M treatment groups, respectively. In the nonabuse cohort, the median (95% CI) time to first psychiatric hospitalization or arrest/incarceration was 371 (165 to N450) days and N 450 days in the oral antipsychotic and PP1M treatment groups, respectively.
Safety
TEAEs are summarized by randomly assigned study treatment and substance abuse comorbidity (Table 3) . TEAEs in the substance abuse cohort were reported in 83.6% of subjects in the oral antipsychotic treatment group compared with 87.7% of subjects in the PP1M treatment group. No significant differences in serious TEAEs or discontinuations due to TEAEs were found between the oral antipsychotic and PP1M treatment groups (25.4% vs 18.5% and 6.7% vs 11.5%, respectively) in the substance abuse cohort. TEAEs in the nonabuse cohort were reported in 78.6% of subjects in the oral antipsychotic treatment group versus 84.4% of subjects in the PP1M treatment group. No significant differences were seen in serious TEAEs or discontinuations due to TEAEs between the oral antipsychotic and PP1M treatment groups (22.6% vs 18.8% and 11.9% vs 13.5%, respectively) in the nonabuse cohort. There were no deaths reported as TEAEs in the oral antipsychotic treatment groups in either cohort. One death was reported in the PP1M treatment group within the nonabuse cohort and was considered by the investigator to be unlikely related to study drug (Alphs et al., 2015) . Within the substance abuse cohort, the most commonly reported TEAEs in the oral antipsychotic versus PP1M treatment groups were insomnia (14.2% vs 20.0%), depression (11.9% vs 8.5%), anxiety (11.2% vs 8.5%), akathisia (9.7% vs 13.1%), injection site pain (0% vs 22.3%), and weight increase (6.7% vs 10.8%). Within the nonabuse cohort, the most commonly reported TEAEs in the oral antipsychotic versus PP1M treatment groups were insomnia (9.5% vs 16.7%), weight increase (8.3% vs 16.7%), anxiety (3.6% vs 14.6%), depression (2.4% vs 9.4%), sedation (10.7% vs 5.2%), akathisia (4.8% vs 9.4%), and injection site pain (0% vs 13.5%).
Extrapyramidal symptom (EPS)-related TEAEs (oral antipsychotic vs PP1M) and weight increases of ≥7% were reported in (22.4% vs 26.9% and 19.0% vs 30.7%, respectively) in the substance abuse cohort (Table  3) . The respective groups (oral antipsychotic vs PP1M) in the nonabuse cohort reported 15.5% vs 24.0% and 17.9% vs 38.0% (Table 3) . Prolactinrelated TEAEs were less frequent in the oral antipsychotic treatment groups compared with the PP1M treatment groups in both the substance abuse and nonabuse cohorts (6.7% vs 30.8% and 2.4% vs 17.7%, respectively) (Table 3) .
Discussion
Those with a dual diagnosis of mental illness and substance abuse are overrepresented in the CJS and represent a disproportionately large contribution to unmet public health treatment needs. Those with schizophrenia and comorbid substance abuse have been shown to incur significantly greater healthcare utilization and costs for use of institutional services (i.e., hospital, emergency, and jail) (Bartels et al., 1993) , underscoring the need for more effective treatments for this at-risk population.
This exploratory analysis found that substance abuse was present in a substantial proportion of schizophrenia patients with a history of incarceration. Almost 60% of the PRIDE population had comorbid substance abuse by the definitions employed here. This is higher than the rates reported in epidemiological studies for the overall schizophrenia population, which have reported lifetime and current prevalence rates of 47% and 27%, respectively (De Witte et al., 2013; Swendsen et al., 2011) . Although PP1M was not able to reverse entirely the deleterious effects of substance abuse, this post hoc analysis showed that PP1M was more effective than oral antipsychotics in delaying time to treatment failure in both the substance abuse and the nonabuse cohorts.
Nonadherence to antipsychotic medication in subjects with schizophrenia can lead to relapse, hospitalization, and arrests or CJS contact (Ascher-Svanum et al., 2010; Lang et al., 2010; Higashi et al., 2013) . The PRIDE study found that arrest or incarceration was the preeminent driver of treatment failure in the population enrolled in that study. This finding was more pronounced for the substance abuse cohort, suggesting that comorbid substance abuse significantly impacts these public health outcomes in subjects with schizophrenia.
Treatment with PP1M was well tolerated in both cohorts. The adverse event profile for PP1M observed in this analysis was similar to that of previous clinical trials Gopal et al., 2010; Markowitz et al., 2013) and was numerically greater for PP1M than for oral antipsychotics. A potential driver of a lower adverse event rate in the oral antipsychotic group may have been the ability to deselect an agent that the patient and/or clinician may have regarded as poorly tolerated. Furthermore, the numerical difference observed between the two cohorts may be related to more consistent treatment with PP1M, which could consequently lead to an increased overall exposure in this treatment group. No increase in sedation side effects was seen in the substance abuse cohort and no new safety issues were detected. The overall proportion of TEAEs reported by subjects in both the substance abuse and nonabuse cohorts was similar; evidence from this trial suggests slightly different TEAE profiles between the two cohorts. Hazard ratios comparing efficacy for PP1M vs oral treatments were similar for polysubstance use and single-substance abuse groups.
Interpretation of the results reported here is constrained by several methodological limitations. Foremost among these is that the results were based on a post hoc identification of substance abuse and nonabuse cohorts. The definition of "substance abuse" was based on the DSM-IV criteria, which was the current version of the DSM at the time that PRIDE was designed and conducted. Subjects classified in the nonabuse cohort might have a history of and/or concurrent substance use that did not meet the "abuse" criteria defined in this exploratory investigation. Using a more stringent or relaxed criteria might shift the relative risk estimations. In addition, the small sample sizes resulting from development of the two new analytical cohorts limit the power and generalizability of these findings, and hindered our ability to investigate other aspects of substance abuse, such as severity. Whether PP1M's relative effectiveness to oral antipsychotics among persons with substance abuse may depend on the type and severity of substance abuse remains unknown. It is commonly understood that different substances of abuse can have different destabilizing effects on underlying psychosis. The limited sample of specific substance abuse subtypes evaluated in the PRIDE study, however, prevents confident assessment of this important question.
Although these analyses were not able to be performed in the current analysis, this remains a worthwhile endeavor for further exploration of the impact of particular substance abuse subtypes and severity in future studies. The apparently lessened treatment response to PP1M observed in the substance abuse cohort highlights the importance of managing comorbid substance abuse in the schizophrenia population. This is likely to require multidisciplinary approaches beyond those employed in the PRIDE study. Methods might include individual and group counseling, residential treatment, intensive outpatient treatment, case management, recovery support services, 12-step fellowship programs, and/or peer support. Engagement in such therapies by individuals with schizophrenia and a recent history of incarceration is likely to be particularly challenging because this population, which faces poverty, homelessness, and a general lack of access to services, is often poorly connected to the traditional mental health system.
Conclusions
Greater treatment effects were seen with PP1M compared with oral antipsychotics in both the substance abuse and nonabuse cohorts of patients with schizophrenia. The effect of PP1M versus oral antipsychotics was attenuated in the substance abuse cohort. This indicates that the benefits of increased treatment exposure and elimination of adherence uncertainty obtained from LAI antipsychotic treatment may not be sufficient to overcome the negative impact of substance abuse in this vulnerable population. Given the dearth of research pertaining to these patients, there would be value in reconfirming the exploratory findings herein, with randomized controlled studies comparing LAIs to oral antipsychotics in schizophrenia patients with substance abuse. Such studies might also incorporate psychosocial therapies directed at treating substance abuse to help mitigate its impact on schizophrenia treatment outcome.
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